Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers

American Journal of Surgery

Volumn 174, Issue 3, 1997, Pages 258-265

  Vetto, John T ^a   Lum, Sharon ^b   Morris, Arden ^b   Sicotte, Mary ^b   Davis, Jennifer ^b   Lemon, Michael ^b   Weinberg, Andrew ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER INFILTRATION; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MELANOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; TISSUE DISTRIBUTION;

ANTIGENS, CD27; CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; HEAD AND NECK NEOPLASMS; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHOCYTES; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MEMBRANE GLYCOPROTEINS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR; SKIN NEOPLASMS;

EID: 0030778972     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(97)00139-6     Document Type: Article

References (36)

1. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell co-stimulation. Ann Rev Immunol. 1996;14:233.
2. Rosenstein M, Eberlein T, Rosenberg S. Adoptive immunotherapy of established syngeneic solid tumors: role of T-lymphoid cell populations. J Immunol. 1984;132:2117-2122.
3. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. NEJM. 1996;334:1717-1725.
4. Godfrey WR, Fagnoni FF, Harara MA, et al. Identification of a human Ox40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J Exp Med. 1994;180:757-762.
5. Weinberg AD, Lemon M, Jones AJ, et al. The OX-40 antibody selects for autoantigen specific V beta 8.2+ T cells within the spinal cord of Lewis rats with autoimmune encephalomyelitis. J Neurosci Res. 1996;43:42-49.
6. Weinberg AD, Wallin JJ, Jones RE, et al. Target organ specific up regulation of the MRC OX-40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with experimental autoimmune encephalomyelitis. J Immunol. 1994;152:4712-4721.
7. Miltenyi S, Muller W, Weichel W, et al. High gradient magnetic cell separation with MACS. Cytometry. 1990;11:231-238.
8. Chomeczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanated-pheno-chloroform extraction. Ann Biochem. 1987;162:156-159.
9. Chow YK, Morrison WJ, Weinberg AD, et al. Immunity to TCR peptides in multiple sclerosis: T cell recognition of V beta 5.2 and V beta 6.1 CDR2 peptides. J Immunol. 1994;152:2520-2529.
10. Hintzen RQ, de Jong R, Lens SMA, van Lier RAW. CD27: a marker and mediator of T-cell activation? Immunology Today. 1994;15:307-311.
11. Callard R, Armitage RJ, Fanslow WC, Spriggs MK. CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunology Today. 1993;14:559-564.
12. Miyawaki T, Uehara T, Nibu R, et al. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol. 1992;149:3753-3758.
13. Watanabe-Fukunaga R, Brannan CI, Copeland NG, et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356:314-317.
14. Godfrey WR, Fagnoni FF, Harara MA, et al. Identification of a human OX-40 ligand, a co-stimulator of CD4+ T cells with homology to tumor necrosis factor. J Exp Med. 1994;180:757.
15. Baum PR, Gayle RB, Ramsdell F, et al. Molecular characterization of immune and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO. 1994;13:3992-4001.
16. Paterson DJ, Jefferies WA, Green JR, et al. Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Molecular Immunol. 1987;24:1281-1290.
17. Mallett S, Fossum S, Barclay AN. Characterization of die MRC OX-40 antigen of activated CD4 positive T lymphocytes - a molecule related to nerve growth factor receptor. EMBO. 1990;9:1063-1068.
18. Calderhead DM, Buhlman JE, van den Eertwegh AJM, et al. Cloning of mouse OX-40: a T cell activation marker that may mediate T-B cell interactions. J Immunol. 1993;151:5261-5271.
19. Latza U, Durkop H, Schnittger S, et al. The human OX-40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen. Eur J Immunol. 1994;24:677-683.
20. Miura S, Ohtani K, Numata N, et al. Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator P40tax. Mol Cell Biol. 1991;11:1313-1325.
21. Stuber E, Neurath M, Calderhead D, et al. Crosslinking of OX-40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity. 1995;2:507-521.
22. Imura A, Hori T, Imada K, et al. The human OX-40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med. 1996;183:2185-2195.
23. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA. 1995;45:8-30.
24. Norris CM, Cady B. Head, neck, and thyroid cancer. In: Holleg AL, Fink DJ, Murphey GP, eds: American Cancer Society Textbook of Clinical Oncology. Atlanta: American Cancer Society; 1991:306-328.
25. Urist MM. Surgical management of primary cutaneous melanoma. CA. 1996;46:217-224.
26. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med. 1996;183:2533-2540.
27. Vandenbark AA, Gill T, Offner H. A myelin basic protein specific T lymphocyte line which mediates EAE. J Immunol. 1985;135:223-228.
28. Swanborg RH. Autoimmune effector cells. V. A monoclonal antibody specific for rat helper T lymphocytes inhibits adoptive transfer of auto-immune encephalomyelitis. J Immunol. 1983; 130:1503-1505.
29. Ortiz-Ortiz L, Nakamura RM, Weigle WO.. T cell requirement for EAE induction in the rat. J Immunol. 1976;117:576-578.
30. Hickey WF. Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation. Brain Pathol. 1991;1:97-105.
31. Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res. 1991;28:254-260.
32. Weinberg AD, Bourdette DN, Sullivan TJ, et al. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nature Med. 1996; 2:183-189.
33. Morris A, Vetto J, Lemon M, et al. Successful transfection of the OX-40 ligand in murine and human tumor cell lines. Proc Am Assoc Cancer Res. 1997;38:401.
34. Dubey C, Croft M, Swain SL. Co-stimulatory requirements of naive CD4+ T cells: ICAM-1 or B-7 can costimulate naive CD4 T cell activation but both are required for optimum response. J Immunol. 1995;155:45-57.
35. Nabel GJ, Chang AE, Nabel EG, et al. Immunotherapy of malignancy by in vivo gene transfer into tumors. Hum Gene Ther. 1992;3:399-410.
36. Wahl WL, Plautz GF, Fox BA, et al. Generation of therapeutic lymphocytes after in vivo transfection of tumor with a gene encoding allelic Class I MHC antigen. Surg Forum. 1992;63:476-479.